Bisphosphonates in early multiple myeloma [1]

European Journal of Haematology

Volumn 71, Issue 3, 2003, Pages 231-232

  Sezer, Orhan ^a   Jakob, Christian ^a   Zavrski, Ivana ^a   Heider, Ulrike ^a   Fleissner, Claudia ^a   Freund, Mathias ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID; ZOLEDRONIC ACID;

APOPTOSIS; DRUG EFFECT; DRUG EFFICACY; HUMAN; LETTER; MEDICAL LITERATURE; MULTIPLE MYELOMA; MYELOMA CELL; OSTEOCLAST; OSTEOLYSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PUBLICATION;

DIPHOSPHONATES; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE MYELOMA;

EID: 0042334476     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2003.00116.x     Document Type: Letter

References (17)

1. JANTUNEN E. Bisphosphonate therapy in multiple myeloma: past, present, future. Eur J Haematol 2002;69:257-264.
2. SEZER O, HEIDER U, JAKOB C, EUCKER J, POSSINGER K. Human bone marrow myeloma cells express RANKL. J Clin Oncol 2002;20:353-354.
3. SEZER O, HEIDER U, JAKOB C, ZAVRSKI I, EUCKER J, POSSINGER K, SERS C, KRENN V. Immunocytochemistry reveals RANKL expression of myeloma cells. Blood 2002;99:4646-4647.
4. SEZER O, HEIDER U, ZAVRSKI I, KÜHNE CA, HOFBAUER LC. RANK ligand and osteoprotegerin in myeloma bone disease. Blood 2003;101:2094-2098.
5. HEIDER U, JAKOB C, ZAVRSKI I, LANGELOTZ C, FLEISSNER C, SCHULZ CO, EUCKER J, POSSINGER K, HOFBAUER LC, SEZER O. Expression of receptor activator of NF-κB ligand (RANKL) on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Blood 2002;100:808a.
6. HEIDER U, LANGELOTZ C, JAKOB C, ZAVRSKI I, FLEISSNER C, EUCKER J, POSSINGER K, HOFBAUER LC, SEZER O. Expression of receptor activator of NF-κB ligand (RANKL) on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Clin Cancer Res 2003;9:1436-1440.
7. SEZER O, JAKOB C, EUCKER J, NIEMÖLLER K, GATZ F, WERNECKE KD, POSSINGER K. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma. Eur J Haematol 2001;66:83-88.
8. NIEMÖLLER K, JAKOB C, HEIDER U, ZAVRSKI I, EUCKER J, KAUFMANN O, POSSINGER K, SEZER O. Bone marrow angiogenesis and its correlation with other disease characteristics in multiple myeloma in stage I versus stage II-III. J Cancer Res Clin Oncol 2003;129:234-238.
9. JAKOB C, ZAVRSKI I, HEIDER U, BRUX B, EUCKER J, LANGELOTZ C, SINHA P, POSSINGER K, SEZER O. Bone resorption parameters carboxy-terminal telopeptide of type-I collagen (ICTP), amino-terminal collagen type-I telopeptide (NTx) and deoxypyridinoline (Dpd) in MGUS and multiple myeloma. Eur J Haematol 2002;69:37-42.
10. JAKOB C, ZAVRSKI I, HEIDER U, LANGELOTZ C, SCHULZ CO, FLEISSNER C, SCHWEIGERT M, EUCKER J, POSSINGER K, SEZER O. Serum levels of carboxy-terminal telopeptide of type-I collagen (ICTP) as a surrogate marker for bone involvement in patients with multiple myeloma showing skeletal abnormalities in MRI but lacking osteolyses in conventional radiography. Blood 2002;100:599a.
11. JAKOB C, ZAVRSKI I, HEIDER U, et al. Serum levels of carboxy-terminal telopeptide of type-I collagen (ICTP) are elevated in patients with multiple myeloma showing skeletal manifestations in magnetic resonance imaging but lacking lytic bone lesions in conventional radiography. Clin Cancer Res 2003;9:3047-3051.
12. APARICIO A, GARDNER A, TU Y, SAVAGE A, BERENSON J, LICHTENSTEIN A. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 1998;12:220-229.
13. DERENNE S, AMIOT M, BARILLE S, COLLETTE M, ROBILLARD N, BERTHAUD P, HAROUSSEAU JL, BATAILLE R. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res 1999;14:2048-2056.
14. SANTINI D, VINCENZI B, AVVISATI G, DICUONZO G, BATTISTONI F, GAVASCI M, SALERNO A, DENARO V, TONINI G. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 2002;8:1080-1084.
15. WOOD J, BONJEAN K, RUETZ S, BELLAHCENE A, DEVY L, FOIDART JM, CASTRONOVO V, GREEN JR. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002;302:1055-1061.
16. YACCOBY S, PEARSE RN, JOHNSON CL, BARLOGIE B, CHOI Y, EPSTEIN J. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 2002;116:278-290.
17. CROUCHER PI, DE HENDRIK R, PERRY MJ, HIJZEN A, SHIPMAN CM, LIPPITT J, GREEN J, VAN MARCK E, VAN CAMP B, VANDERKERKEN K. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 2003;18:482-492.